HI
CORT icon

HBK Investments’s Corcept Therapeutics CORT Stock Holding History

HBK Investments’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-26,594
Closed -$513K – 992
2017
Q3 		$513K Sell
26,594
-48,006
-64% -$716K ﹤0.01% 787
2017
Q2 		$880K Buy
+74,600
New +$811K 0.01% 609

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

HBK Investments's CORT Position: Q4 2017 in Review

HBK Investments sold out of Corcept Therapeutics (CORT) in Q4 2017, closing a stake of 26,594 shares — an estimated $513K sold.

HBK Investments first reported a position in CORT in Q2 2017 and held it in 2 quarters. The position peaked at $880K in Q2 2017. 190 funds tracked by Wall St. Rank hold CORT as of Q4 2017.

  • HBK Investments reported no remaining Corcept Therapeutics position as of Q4 2017 after selling out during the quarter.
  • HBK Investments sold 26,594 Corcept Therapeutics shares in Q4 2017, an estimated $513K.
  • HBK Investments first reported a position in Corcept Therapeutics in Q2 2017 and held it in 2 quarters.
  • HBK Investments's Corcept Therapeutics position peaked at $880K in Q2 2017.
  • 190 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2017.

Based on HBK Investments's 13F filing for Q4 2017, filed 14 Feb 2018.